

EMA/49374/2015

European Medicines Agency decision

P/0033/2015

of 6 March 2015

on the acceptance of a modification of an agreed paediatric investigation plan for house dust mites allergen extracts (EMA-000319-PIP01-08-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0033/2015

of 6 March 2015

on the acceptance of a modification of an agreed paediatric investigation plan for house dust mites allergen extracts (EMA-000319-PIP01-08-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/72/2009 issued on 20 April 2009, the decision P/252/2009 issued on 22 December 2009, and the decision P/160/2011 issued on 4 July 2011,

Having regard to the application submitted by Stallergenes on 27 October 2014 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 January 2015, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for house dust mites allergen extracts, sublingual tablet, sublingual use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Stallergenes, 6 Rue Alexis de Tocqueville, 92183 – Antony, France.

Done at London, 6 March 2105

For the European Medicines Agency
Jordi Llinars Garcia
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/683120/2014

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-000319-PIP01-08-M03

Scope of the application

Active substance(s):

House dust mites allergen extracts

Condition(s):

Treatment of allergic rhinitis

Treatment of asthma

Pharmaceutical form(s):

Sublingual tablet

Route(s) of administration:

Sublingual use

Name / corporate name of the PIP applicant:

Stallergenes

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Stallergenes submitted to the European Medicines Agency on 27 October 2014 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/72/2009 issued on 20 April 2009, the decision P/252/2009 issued on 22 December 2009, and the decision P/160/2011 issued on 4 July 2011.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 19 November 2014.



Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 16 January 2015

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of allergic rhinitis

The waiver applies to:

- Newborns, infants and children from birth to less than 5 years;
- for house dust mites allergen extracts, sublingual tablets, sublingual use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

1.2. Condition:

Treatment of asthma

The waiver applies to:

- All subsets of the paediatric population;
- for house dust mites allergen extracts, sublingual tablets, sublingual use;
- on the grounds that the specific medicinal product is likely to be ineffective.

2. Paediatric investigation plan

2.1. Condition:

Treatment of allergic rhinitis

2.1.1. Indication(s) targeted by the PIP

Treatment of allergic rhinitis due to house dust mites

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 5 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Sublingual tablet

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	3	Study 1 Embryo-foetal development in rats Study 2 Embryo-foetal development in rabbits Study 3 Juvenile toxicity study in rats
Clinical studies	1	Study 4 Randomised, double-blind, placebo-controlled safety and efficacy study of sublingual immunotherapy administered as allergen-based tablet once daily to children from 5 to less than 18 years, suffering from house dust mite allergic rhinitis.
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2011
Deferral for one or more measures contained in the paediatric investigation plan:	No